肺动脉高压代谢组学:从病理机制到治疗靶点

doi:10.16352/j.issn.1001-6325.2024.08.1074

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (8): 1074-1079.doi: 10.16352/j.issn.1001-6325.2024.08.1074

• 特邀专题：肺动脉高压 • 上一篇下一篇

肺动脉高压代谢组学:从病理机制到治疗靶点

邓渊瑞¹, 王晓建^1,2,3,4*

中国医学科学院北京协和医学院国家心血管病中心阜外医院 1.心血管疾病国家重点实验室;2.肺血管医学重点实验室,北京 100037;
3.阜外华中心血管病医院国家卫生健康委员会心血管疾病再生医学重点实验室国家心血管病中心华中分中心,河南郑州 451460;
4.山西医科大学第一医院国家卫生健康委尘肺病重点实验室,山西太原 030001

收稿日期:2024-06-06 修回日期:2024-06-21 出版日期:2024-08-05 发布日期:2024-07-24
通讯作者: ^*wang_xiaojian@vip.163.com
基金资助:
国家自然科学基金面上项目(82170408);北京市自然科学基金(7222142);中央级公益性科研院所基本科研业务费(2020-PT320-005);中国医学科学院阜外医院高水平医院临床科研攻关项目(2023-GSP-GG-24);心血管疾病国家重点实验室青年项目(2023QN-01)

Metabolomics of pulmonary hypertension: from pathological mechanisms to therapeutic targets

DENG Yuanrui¹, WANG Xiaojian^1,2,3,4*

1. State Key Laboratory of Cardiovascular Disease; 2. Key Laboratory of Pulmonary Vascular Medicine, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037;
3. National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Fuwai Central-China Hospital, Central-China Branch of National Center for Cardiovascular Diseases, Zhengzhou 451460;
4. Key Laboratory of Pneumoconiosis, National Health Commission, First Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2024-06-06 Revised:2024-06-21 Online:2024-08-05 Published:2024-07-24
Contact: ^*wang_xiaojian@vip.163.com

摘要/Abstract

摘要： 肺动脉高压(pulmonary hypertension, PH)是一种以肺血管重构为主要病理特征的恶性心血管病。患者通常存在显著代谢异常,包括能量代谢紊乱、脂质代谢改变和氨基酸代谢失衡。这些代谢异常与肺血管重塑、内皮功能障碍和右心室肥厚等病理生理过程密切相关。近年来,肺动脉高压代谢组学进展迅速,从早期发现代谢差异产物到目前挖掘潜在治疗靶点,代谢组学在肺动脉高压疾病中的应用加深了人们对PH发病机制的理解,加速了潜在治疗靶点的发现与筛选,部分成果已经转化到临床,有助于肺动脉高压的诊断、治疗和预后评估。

关键词: 代谢组学, 肺动脉高压

Abstract: Pulmonary hypertension (PH) is a severe cardiovascular disease characterized primarily by pulmonary vascular remodeling. Patients with PH typically exhibit significant metabolic abnormalities including disruptions in energy metabolism, alterations in lipid and amino acids metabolism. These metabolic disturbances are closely linked to pathophysiological processes such as pulmonary vascular remodeling, endothelial dysfunction and right ventricular hypertrophy. In recent years, there has been rapid progress in the field of metabolomics related to PH. From the early identification of differential metabolic products to the current exploration of potential therapeutic targets, metabolomics has deepened the understanding of the pathogenesis of PH. These researches have accelerated the discovery and screening of potential therapeutic targets, with some findings already translated into clinical practice to support diagnosis, treatment and prognostic evaluation of PH.

Key words: metabolomics, pulmonary hypertension

中图分类号:

R543.2

邓渊瑞, 王晓建. 肺动脉高压代谢组学:从病理机制到治疗靶点[J]. 基础医学与临床, 2024, 44(8): 1074-1079.

DENG Yuanrui, WANG Xiaojian. Metabolomics of pulmonary hypertension: from pathological mechanisms to therapeutic targets[J]. Basic & Clinical Medicine, 2024, 44(8): 1074-1079.

参考文献

[1] Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review[J]. JAMA, 2022, 327: 1379-1391.
[2] Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10: 1. doi:10.1038/s41572-023-00486-7.
[3] D′Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]. Ann Intern Med, 1991, 115: 343-349.
[4] Peacock AJ, Murphy NF, Mcmrray JJV, et al. An epidemiological study of pulmonary arterial hypertension[J]. Eur Respir J, 2007, 30: 104-109.
[5] Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension[J]. Chest, 2007, 132: 373-379.
[6] Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension[J]. Am J Respir Crit Care Med, 2012, 185: 260-266.
[7] Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect[J]. Eur J Clin Invest, 2013, 43: 855-865.
[8] Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension[J]. Cell Metab, 2014, 19: 558-573.
[9] Pokharel MD, Marciano DP, Fu P, et al. Metabolic reprogramming, oxidative stress, and pulmonary hypertension[J]. Redox Biol, 2023, 64: 102797. doi:10.1016/j.redox.2023.102797.
[10] Pauling L, Robinson AB, Teranishi R, et al. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography[J]. Proc Natl Acad Sci USA, 1971, 68: 2374-2376.
[11] Bujak R, García A, Rupérez FJ, et al. Metabolomics reveals metabolite changes in acute pulmonary embolism[J]. J Proteome Res, 2014, 13: 805-816.
[12] Lewis GD, Ngo D, Henmes AR, et al. Metabolic profiling of right ventricular-pulmonary vascular function reveals circulating biomarkers of pulmonary hypertension[J]. J Am Coll Cardiol, 2016, 67: 174-189.
[13] Bujak R, Mateo J, Blanco I, et al. New biochemical insights into the mechanisms of pulmonary arterial hypertension in humans[J]. PLoS One, 2016, 11: e0160505. doi:10.1371/journal.pone.0160505.
[14] Rhodes CJ, Ghataorhe P, Wharton J, et al. Plasma metabolomics implicates modified transfer RNAs and altered bioenergetics in the outcomes of pulmonary arterial hypertension[J]. Circulation, 2017, 135: 460-475.
[15] Fessel JP, Hamid R, Wittmann BM, et al. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals wides-pread metabolic reprogramming[J]. Pulm Circ, 2012, 2: 201-213.
[16] Zhao Y, Peng J, Lu C, et al. Metabolomic heterogeneity of pulmonary arterial hypertension[J]. PLoS One, 2014, 9: e88727. doi:10.1371/journal.pone.0088727.
[17] Zhao YD, Chu L, Lin K, et al. A biochemical approach to understand the pathogenesis of advanced pulmonary arterial hypertension: metabolomic profiles of arginine, sphingosine-1-phosphate, and heme of human lung[J]. PLoS One, 2015, 10: e0134958. doi:10.1371/journal.pone.0134958.
[18] Voelkel NF, Cool C, Lee SD, et al. Primary pulmonary hypertension between inflammation and cancer[J]. Chest, 1998, 114: 225S-230S.
[19] Rai PR, Cool CD, King JAC, et al. The cancer paradigm of severe pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2008, 178: 558-564.
[20] Koppenol WH, Bounds PL, Dang CV. Otto Warburg′s contributions to current concepts of cancer metabolism[J]. Nat Rev Cancer, 2011, 11: 325-337.
[21] Zhao L, Ashek A, Wang L, et al. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments[J]. Circulation, 2013, 128: 1214-1224.
[22] Hernandez SD, Sanders L, Freeman S, et al. Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment[J]. Sci Rep, 2020, 10: 413. doi:10.1038/s41598-019-57200-5.
[23] Cao Y, Zhang X, Wang L, et al. PFKFB3-mediated endothelial glycolysis promotes pulmonary hypertension[J]. Proc Natl Acad Sci USA, 2019, 116: 13394-13403.
[24] Wang L, Zhang X, Cao Y, et al. Mice with a specific deficiency of pfkfb3 in myeloid cells are protected from hypoxia-induced pulmonary hypertension[J]. Br J Pharmacol, 2021, 178: 1055-1072.
[25] Mey JT, Hari A, Axelrod CL, et al. Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study[J]. Eur Respir J, 2020, 55: 1901700. doi:10.1183/13993003.01700-2019.
[26] Legchenko E, Chouvarine P, Borchert P, et al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation[J]. Sci Transl Med, 2018, 10: eaao0303. doi:10.1126/scitranslmed.aao0303.
[27] Sutendra G, Bonnet S, Rochefort G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension[J]. Sci Transl Med, 2010, 2: 44ra58. doi:10.1126/scitranslmed.3001327.
[28] Philip N, Pi H, Gadkari M, et al. Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension[J]. Pulm Circ, 2023, 13: e12205. doi:10.1002/pul2.12205.
[29] Michelakis ED, Gurtu V, Webster L, et al. Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients[J]. Sci Transl Med, 2017, 9: eaao4583. doi:10.1126/scitranslmed.aao4583.
[30] Alotaibi M, Shao J, Pauciulo MW, et al. Metabolomic profiles differentiate scleroderma-PAH from idiopathic PAH and correspond with worsened functional capacity[J]. Chest, 2023, 163: 204-215.
[31] Simpson CE, Hemnes AR, Griffiths M, et al. Metabolo-mic differences in connective tissue disease-associated versus idiopathic pulmonary arterial hypertension in the PVDOMICS cohort[J]. Arthritis Rheumatol, 2023, 75: 2240-2251.
[32] Swietlik EM, Ghataorhe P, Zalewska KI, et al. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension[J]. Eur Respir J, 2021, 57: 2003201. doi:10.1183/13993003.03201-2020.
[33] Brittain EL, Niswender K, Agrawal V, et al. Mechanistic phase II clinical trial of metformin in pulmonary arterial hypertension[J]. J Am Heart Assoc, 2020, 9: e018349. doi:10.1161/JAHA.120.018349.
[34] Gao X, Zhang Z, Li X, et al. Macitentan attenuates chronic mountain sickness in rats by regulating arginine and purine metabolism[J]. J Proteome Res, 2020, 19: 3302-3314.
[35] He YY, Yan Y, Chen JW, et al. Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease[J]. Acta Pharmacol Sin, 2022, 43: 1710-1720.
[36] He YY, Yan Y, Jiang X, et al. Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension[J]. Eur Respir J, 2020, 56: 2000522. doi:10.1183/13993003.00522-2020.
[37] Luo Y, Qi X, Zhang Z, et al. Inactivation of malic enzyme 1 in endothelial cells alleviates pulmonary hypertension[J]. Circulation, 2024, 149:1354-1371.
[38] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Heart J, 2022, 43: 3618-3731.
[39] Harbaum L, Rhodes CJ, Otero NEZP, et al. The application of ‘omics’ to pulmonary arterial hypertension[J]. Br J Pharmacol, 2021, 178: 108-120.
[40] Guo TT, Deng YR, Huang X, et al. Untargeted metabolomics reveal the metabolic profile of normal pulmonary circulation[J]. Respir Med, 2023, 217: 107369. doi:10.1016/j.rmed.2023.107369.

肺动脉高压代谢组学:从病理机制到治疗靶点

Metabolomics of pulmonary hypertension: from pathological mechanisms to therapeutic targets

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡崧, 华潞, 张健. 肺动脉高压的抗凝治疗:必要性与困境[J]. 基础医学与临床, 2024, 44(8): 1062-1067.
[2]	钱喜锋, 华潞. 炎性细胞与动脉性肺动脉高压血管重塑[J]. 基础医学与临床, 2024, 44(8): 1080-1087.
[3]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[4]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[5]	余志鑫, 邙新雨, 邹定峰, 缪时英, 宋伟, 李凯. 腹腔注射白消安对精原干细胞代谢特征的影响[J]. 基础医学与临床, 2024, 44(6): 793-799.
[6]	魏斌, 段红杰, 柴家科. 代谢组学在重伤诊治中的研究进展[J]. 基础医学与临床, 2024, 44(4): 562-567.
[7]	刘幸幸, 王威威, 袁好鑫. 内质网应激在低氧性肺动脉高压中作用的研究进展[J]. 基础医学与临床, 2023, 43(5): 848-851.
[8]	缪昊真, 陶磊, 宋冰洁, 张奇军. 代谢重编程在心房颤动发生中作用的研究进展[J]. 基础医学与临床, 2023, 43(11): 1718-1722.
[9]	肖晓莲, 刘晓燕, 朱文凤, 杨晔宏, 杨俊涛, 孙伟. 尿液代谢组学非靶向质谱分析法两种采集模式的比较[J]. 基础医学与临床, 2021, 41(5): 729-734.
[10]	李发美, 余再新. 神经酰胺的功能及其在肺动脉高压中的作用[J]. 基础医学与临床, 2021, 41(2): 267-271.
[11]	何权, 刘丹瑜, 叶君, 张艳丽, 朱华栋, 蒋澄宇, 徐军. 5-羟色胺对重症社区获得性肺炎严重程度的预测研究[J]. 基础医学与临床, 2020, 40(9): 1195-1200.
[12]	邢书娟, 董明清, 杨力侠, 罗颖. 两种肺动脉高压模型小鼠的基因表达谱分析[J]. 基础医学与临床, 2020, 40(11): 1462-1467.
[13]	刘昕朋张斌. 细胞代谢组学研究方法和应用[J]. 基础医学与临床, 2019, 39(3): 414-418.
[14]	王海燕王刚张晓岩李菊英贺菊香李生花. 二十味沉香丸增强低氧性肺动脉高压大鼠肺组织PKC-α表达[J]. 基础医学与临床, 2014, 34(6): 844-846.
[15]	王为王迁赵久良李梦涛曾小峰. 利妥昔单抗治疗系统性红斑狼疮相关肺动脉高压的前景[J]. 基础医学与临床, 2010, 30(3): 317-319.